<DOC>
	<DOCNO>NCT00768612</DOCNO>
	<brief_summary>This study evaluate clinical safety tolerability vabicaserin Japanese subject sudden worsening symptom schizophrenia . The study also assess efficacy vabicaserin compare risperidone .</brief_summary>
	<brief_title>Study Evaluating Safety Tolerability Vabicaserin Patients With Sudden Worsening Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Male female subject &gt; =20 = &lt; 65 year age Current diagnosis DSMIVTR diagnosis schizophrenia type ( 295.10 , 295.30 295.90 ) Total PANSS score &gt; =70 = &lt; 120 Subjects hospitalize Current Axis I primary psychiatric diagnosis schizophrenia A score 3 CDSS question 8 pertains suicide</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Acute , Schizophrenia , Phase2a , Vabicaserin</keyword>
</DOC>